Idiopathic pulmonary fibrosis trials in Israel

In Israel 6 Also abroad 111

6 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Where
Ashdod, Ashkelon, Be’er Ya‘aqov, Hadera, Jerusalem, Kafr Saba, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv
Age
40 years and over
People
324 worldwide
Run by
Contineum Therapeutics
See details and how to joinNCT07284459 · EU 2025-521901-42-00
No phaseTaking people
Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Where
Ashkelon, Haifa, Ramat Gan, Tel Aviv
Age
18 years and over
People
70
Run by
Avraham Unterman
See details and how to joinNCT07919015
Phase 3Not yet taking people in Israel
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Where
Petah Tikva
Age
18 years and over
People
2,380 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07441408 · EU 2025-522373-10-00
Phase 2Taking people
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
Where
Ashkelon, Jerusalem, Kfar Saba, Petah Tikva, Rehovot
Age
40 years and over
People
359 worldwide
Run by
AstraZeneca
See details and how to joinNCT07652658
Phase 3Enrolling by invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Where
Ashkelon, Hadera, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv
Age
40 years and over
People
1,850 worldwide
Run by
United Therapeutics
See details and how to joinNCT04905693
Phase 3Taking people
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Where
Ashkelon, Hadera, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Rehovot, Tel Aviv
Age
18 years and over
People
698 worldwide
Run by
United Therapeutics
See details and how to joinNCT05943535 · EU 2023-504904-26-00